NavDx retweeted
Naveris first earned our attention and investment in 2019, amidst the development of their pioneering liquid biopsy test, NavDx. As the first and only blood test of its kind to be clinically validated, NavDx aids in the detection of HPV-driven cancers with unparalleled accuracy and specificity.
Recently, the company celebrated a significant achievement: receiving the Advanced Diagnostic Laboratory Test (ADLT) designation from the Centers for Medicare & Medicaid Services. This prestigious recognition marks a major milestone toward achieving the broad accessibility required for saving lives at scale.
Congratulations to Piyush Gupta, James McNally, and the entire @NaverisDx team. We are proud of the impact you are making on the world.
businesswire.com/news/home/2…
NavDx retweeted
CMS Designates NavDx Test for HPV-Driven Cancer as ADLT genomeweb.com/molecular-diag…
NavDx retweeted
@RettigEleni reviewing the potential power of HPV ctDNA across the spectrum of disease in HPV+ OPC — at the Boston HNC Symposium 🧐🧬🧪@DrUppaluri @NaverisDx @DanaFarberNews @DanaFarber @FadenLab @BU_Tweets – at Boston, MA
NavDx retweeted
Our work demonstrating the PPV of plasma TTMV-HPV DNA 🧬🩸as a surveillance tool in HPV-driven oropharynx cancers now reported in @CCR_AACR 🧐👀 @DanaFarberNews @jdschoenfeld1 @NaverisDx @FadenLab
aacrjournals.org/clincancerr…
NavDx retweeted
Today at #HNCS22, Dr. Glenn Hanna @HeadNeckMD presents a large study that found a blood test to detect circulating tumor DNA predicts post-treatment recurrence of HPV+ oropharyngeal #cancer @DanaFarberNews @DanaFarber https://xitter.gq/t.co/mhgIrlFGJf
NavDx retweeted
New research presented by @HeadNeckMD demonstrates that a blood test to detect circulating tumor DNA can accurately predict recurrence of #HPV-driven oropharyngeal cancer following treatment: ms.spr.ly/6014wrWOg #HNCS22 #hncsm
NavDx retweeted
ASTRO welcomes our newest Corporate Members @NaverisDx and @TTGimaging. To view the full list of corporate members or to learn more about corporate membership, visit our website: ow.ly/rQIJ50FfjZM #RadOnc
NavDx retweeted
Replying to @BhishamCheraMD
@BhishamCheraMD presenting exciting new findings @ASTRO_org on a blood test for early detection of disease recurrence in patients with HPV+ oropharyngeal cancer. It’s gratifying to see our research benefit patients—great work team! #HPV #oralcancer #ASTRO18 @NaverisDx
NavDx retweeted
A good article highlighting the need for an effective screening test for HPV+ oropharyngeal cancer. Stay tuned...@BhishamCheraMD @ASTRO_org @NaverisDx
Why is #HPV-related #oralcancer on the rise in men? Our Dr. Maura Gillison weighs in: https://xitter.gq/t.co/K2BxDQppkq @sciam
NavDx retweeted
At MIT, IMF’s Christine @Lagarde calls for new tech and policies to meet population growth mitsha.re/ZaYgX
NavDx retweeted
Meet Laurie Glimcher, @DanaFarber's new CEO who turned down @harvardmed https://xitter.gq/t.co/8BShNFZPJX
NavDx retweeted
Doctors might be one step closer to figuring out how to make cancer vaccines work: https://xitter.gq/t.co/0EkqCJ9Js4
NavDx retweeted
Our paper on spatial reconstruction from single cell RNAseq is out @NatureBiotech w/beautiful co-pub by Marioni lab! http://t.co/uJh3CIGq83
NavDx retweeted
#UROP Daphne Superville is modeling human mammary glands in the @GuptaLabMIT #KIimages @WhiteheadInst
NavDx retweeted
The Irvine Lab is reprogramming T cells with a “License to Kill” tumor cells #KIimages @MITdeptofBE @WhiteheadInst
NavDx retweeted
The Samson Lab is studying DNA-repair proteins’ role in chemotherapy resistance #KIimages @MITdeptofBE @MITBiology
NavDx retweeted
Steffen Rickelt is screening for cells’ response to antibodies reactive with metastatic tumors #KIimages
NavDx retweeted
.@robertmarc60, @BWjones & other @uutah researchers are studying metabolic pathways #2015WIA #KIimages
NavDx retweeted
.@auralstates & the Irvine Lab are developing microscopic drug depots to focus the effects of cancer drugs #KIimages



























